BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases through aging biology, has announced its participation in TD Cowen's 45th Annual Health Care Conference.
The conference is scheduled for March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. BioAge will engage in one-on-one meetings during the event, which features presentations, fireside chats, and panel discussions moderated by TD Cowen research team members, covering various healthcare industry aspects.
BioAge Labs (Nasdaq: BIOA), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di prodotti terapeutici per le malattie metaboliche attraverso la biologia dell'invecchiamento, ha annunciato la sua partecipazione al 45° Annual Health Care Conference di TD Cowen.
La conferenza si terrà dal 3 al 5 marzo 2025, presso il Boston Marriott Copley Place a Boston, MA. BioAge parteciperà a incontri one-on-one durante l'evento, che presenterà presentazioni, conversazioni informali e discussioni di panel moderate dai membri del team di ricerca di TD Cowen, coprendo vari aspetti dell'industria sanitaria.
BioAge Labs (Nasdaq: BIOA), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de productos terapéuticos para enfermedades metabólicas a través de la biología del envejecimiento, ha anunciado su participación en la 45ª Conferencia Anual de Atención Médica de TD Cowen.
La conferencia está programada del 3 al 5 de marzo de 2025, en el Boston Marriott Copley Place en Boston, MA. BioAge participará en reuniones uno a uno durante el evento, que contará con presentaciones, charlas informales y paneles de discusión moderados por miembros del equipo de investigación de TD Cowen, abarcando varios aspectos de la industria de la salud.
BioAge Labs (Nasdaq: BIOA)는 노화 생물학을 통한 대사 질환 치료 제품 개발에 집중하는 임상 단계의 생물 의약품 회사로, TD Cowen의 제45회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
컨퍼런스는 2025년 3월 3일부터 5일까지 매사추세츠주 보스턴의 보스턴 메리어트 코플리 플레이스에서 열릴 예정입니다. BioAge는 행사 동안 일대일 미팅에 참여하며, TD Cowen 연구팀이 진행하는 발표, 담화, 패널 토론 등 다양한 헬스케어 산업 측면을 다룰 것입니다.
BioAge Labs (Nasdaq: BIOA), une entreprise biopharmaceutique en phase clinique axée sur le développement de produits thérapeutiques pour les maladies métaboliques à travers la biologie du vieillissement, a annoncé sa participation à la 45e Conférence Annuelle sur les Soins de Santé de TD Cowen.
La conférence est prévue du 3 au 5 mars 2025, au Boston Marriott Copley Place à Boston, MA. BioAge participera à des réunions individuelles durant l'événement, qui comprendra des présentations, des discussions informelles et des tables rondes modérées par des membres de l'équipe de recherche de TD Cowen, couvrant divers aspects de l'industrie de la santé.
BioAge Labs (Nasdaq: BIOA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung therapeutischer Produkte für Stoffwechselerkrankungen durch Altersbiologie konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben.
Die Konferenz findet vom 3. bis 5. März 2025 im Boston Marriott Copley Place in Boston, MA, statt. BioAge wird während der Veranstaltung an persönlichen Meetings teilnehmen, die Präsentationen, informelle Gespräche und Podiumsdiskussionen umfassen, die von Mitgliedern des Forschungsteams von TD Cowen moderiert werden und verschiedene Aspekte der Gesundheitsbranche abdecken.
- None.
- None.
RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.
TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health care industry.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel, structurally differentiated APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
When is BioAge Labs (BIOA) participating in TD Cowen's Healthcare Conference 2025?
What type of meetings will BioAge (BIOA) conduct at the TD Cowen Conference 2025?
What is BioAge Labs' (BIOA) current development focus in 2025?
What activities are included in TD Cowen's 45th Annual Health Care Conference where BIOA is participating?
